ライフサイエンスコーパス: length of hospital stay

1 ent outcomes, antimicrobial stewardship, and length of hospital stay.

2 y endpoints included other complications and length of hospital stay.

3 tilation, high injury severity, or prolonged length of hospital stay.

4 Perforation rate, normal appendix rate, and length of hospital stay.

5 0 days; all-cause mortality at 180 days; and length of hospital stay.

6 reases venous ammonia, time of recovery, and length of hospital stay.

7 es were morbidity, other ileus symptoms, and length of hospital stay.

8 n morbidity, mortality, reoperation rate, or length of hospital stay.

9 vascular events, end-stage renal disease, or length of hospital stay.

10 d visual analogue scales, complications, and length of hospital stay.

11 , cardiac morbidity, functional recovery, or length of hospital stay.

12 algesic requirement, time to ambulation, and length of hospital stay.

13 ol protocols sooner and by possibly reducing length of hospital stay.

14 c therapy; (4) mortality; (5) costs; and (6) length of hospital stay.

15 ause mortality, incidence of infections, and length of hospital stay.

16 ization, faster recovery time, and decreased length of hospital stay.

17 organ dysfunction, nosocomial infection, and length of hospital stay.

18 LDP has lower blood loss and reduced length of hospital stay.

19 reased mortality and morbidity and prolonged length of hospital stay.

20 , mental confusion, functional recovery, and length of hospital stay.

21 in visibility, duration of the procedure and length of hospital stay.

22 ct to carbapenem, was not found to influence length of hospital stay.

23 or post-operative inotropic support, and the length of hospital stay.

24 ype and number of serious adverse events and length of hospital stay.

25 months, adverse events, quality of life, and length of hospital stay.

26 ith prolonged ventilation and with increased length of hospital stay.

27 d cells requirement but with shorter (P=0.6) length of hospital stay.

28 ity, 28-day emergency readmission rates, and length of hospital stay.

29 t not with adjusted in-hospital mortality or length of hospital stay.

30 eness, as well as aiming to reduce costs and length of hospital stay.

31 ecreased intensive care unit utilization and length of hospital stay.

32 a parallel decline in low cardiac output and length of hospital stay.

33 sted odds ratio, 0.62; 95% CI, .29-1.36) nor length of hospital stay.

34 delayed laparotomy in observed patients, and length of hospital stay.

35 nteral nutrition 90 days postoperatively and length of hospital stay.

36 ssociation between consensus CT findings and length of hospital stay.

37 caused by MDROs on morbidity, mortality, and length of hospital stay.

38 omization without increasing side effects or length of hospital stay.

39 ity, complications, major complications, and length of hospital stay.

40 oral intake are critical determinants of the length of hospital stay.

41 postoperative pain, time of ambulation, and length of hospital stay.

42 ecisions about antibiotic administration and length of hospital stay.

43 sequential IV-to-oral therapy may reduce the length of hospital stay.

44 tic fistula, total complications, death, and length of hospital stay.

45 sk for readmission to hospital and potential length of hospital stay.

46 m on duration of mechanical ventilation, and length of hospital stay.

47 re antimicrobial agents divided by the total length of hospital stay.

48 ltidrug-resistant organism colonisation; and length of hospital stay.

49 postoperative pain, complications, QoL, and length of hospital stay.

50 th mild to moderate pancreatitis, may reduce length of hospital stay.

51 omplications, hospital mortality, and median length of hospital stay.

52 t laparoscopic surgery significantly reduced length of hospital stay.

53 tal mortality, duration of organ support, or length of hospital stay.

54 re were no differences in complications, and length of hospital-stay.

55 nce, improve patient outcomes and reduce the length of hospital stays.

56 orbidity and have been shown to increase the length of hospital stays.

57 in practice patterns, diagnostic yields, and lengths of hospital stay.

58 vs 4 of 143 [2.8%]; P < .001) and prolonged length of hospital stay (12 vs 8 days; P = .04).

59 e of reoperation (16.6% vs 21.0%; P = 0.22), length of hospital stay (12.2 vs 12.2; P = 0.99) and rat

60 esophagectomy was associated with a shorter length of hospital stay (16 +/- 6 vs 19 +/- 9 days; P <

61 iagnosis (8.1 +/- 8.5 vs. 9.4 +/- 7.4 h) and length of hospital stay (19.7 +/- 27.8 vs. 23.5 +/- 34.4

62 ine (15 days vs. 28 days), as was the median length of hospital stay (21 days vs. 33 days) (P<0.001 f

63 ypass at high-volume hospitals had a shorter length of hospital stay (3.8 versus 5.1 days, P < 0.01),

64 spital sooner than the 4-dose cohort (median length of hospital stay, 3 vs. 4 days; P=0.004).

65 e used to identify independent predictors of length of hospital stay, 30-day and 365-day mortality.

66 Outcomes of bariatric surgery, including length of hospital stay, 30-day readmission, morbidity,

67 re compared for 30-day and 90-day mortality, length of hospital stay, 30-day unplanned readmission ra

68 P < 0.001, Wilcoxon's signed-rank test], and length of hospital stay (39.7 +/- 71.9 compared with 11.

69 care unit admissions, significantly shorter length of hospital stay (4.34 +/- 4.84 days for LA vs 7.

70 Mean length of hospital stay (5.4 days vs 10.0 days; P < 0.00

71 had percutaneous drainage had a much shorter length of hospital stay (6.1 +/- 4.6 days) than patients

72 +/- 36.1 vs 122.1 +/- 53.5 h; P < .001) and length of hospital stay (6.5 +/- 2.2 vs 8.5 +/- 4.8 days

73 interval [CI]: 1.3-8.5) and a longer median length of hospital stay (7 vs 12 days, P < 0.001).

74 ation, days in an intensive care unit, total length of hospital stay, adjunct therapies and procedure

75 risk-adjusted OR: 6.0, P < 0.001), increased length of hospital stay (adjusted mean difference: 0.89

76 Outcome measures including survival, length of hospital stay, adverse events, and quality of

77 Length of hospital stay after birth (P = .002) and mater

78 fidence interval [CI], .23-2.11; P = .36) or length of hospital stay after infection (relative risk,

79 No significant difference was found in length of hospital stay after intervention between the t

80 VE AND BACKGROUND: Morbidity, mortality, and length of hospital stay after pancreaticoduodenectomy (P

81 The mean (SD) length of hospital stay after TAVR was 8.0 (5.9) days.

82 Increased length of hospital stay among survivors was significantl

83 ssociated with increased morbidity including length of hospital stay and an increased incidence of re

84 The risk-adjusted length of hospital stay and charges were similar between

85 artiles witnessed a significant reduction in length of hospital stay and cost of hospitalization (P<0

86 cognitive impairment associated with longer length of hospital stay and cost, premature withdrawal f

87 tion of nasojejunal tubes promotes decreased length of hospital stay and early initiation of enteral

88 nd COMT genes were associated with a shorter length of hospital stay and less need for treatment.

89 kall score was significantly associated with length of hospital stay and mortality (p < 0.001).

90 r models of the association between FEV1 and length of hospital stay and mortality were adjusted for

91 is an independent predictor of mortality and length of hospital stay and provides significantly more

92 Postoperative length of hospital stay and rates of pancreatic fistula,

93 lity of different NIs to predict outcomes of length of hospital stay and readmission to refine the de

94 The length of hospital stay and the complication rate were n

95 r surgery and was found to be related to the length of hospital stay and the development of complicat

96 The length of hospital stay and the incidence of major compl

97 ibody production, potentially decreasing the length of hospital stay and the need for transfusions.

98 ients with a complicated UTI seems to reduce length of hospital stay and therefore favors patient out

99 examined for association with two outcomes: length of hospital stay and time to all-cause hospital r

100 We assessed temporal trends in length of hospital stay and use of pharmacological and i

101 th more hospital complications and prolonged length of hospital stay and was an independent predictor

102 nt LS also had a significantly shorter total length of hospital stay and were less likely to receive

103 Lengths of hospital stay and hospital charges were simil

104 We used routine blood test results, length of hospital stay, and 30-day mortality to clinica

105 admission, need for mechanical ventilation, length of hospital stay, and 30-day mortality.

106 cause mortality, 30-day all-cause mortality, length of hospital stay, and 30-day readmission rate amo

107 in operating time, a sevenfold reduction in length of hospital stay, and a mean cost savings of $2,6

108 ociated with a decrease in adverse outcomes, length of hospital stay, and cost of hospitalization.

109 ging is similar to CTA in time to diagnosis, length of hospital stay, and cost, with improved prognos

110 PIVH/PVL), retinopathy of prematurity (ROP), length of hospital stay, and days of mechanical ventilat

111 living alone, low ejection fraction (<0.35), length of hospital stay, and depression.

112 ill patients increases morbidity, mortality, length of hospital stay, and healthcare costs.

113 nit admission rate, 30-day readmission rate, length of hospital stay, and hospital costs were collect

114 risk of subsequent ICU admission, increased length of hospital stay, and increased hospital mortalit

115 iving (ADL) dependency, comorbid conditions, length of hospital stay, and laboratory measurements.

116 e to ambulation (6.1 vs 11.5 hours), shorter length of hospital stay, and lower cost (1728 euro vs 23

117 ompared differences in the hospital charges, length of hospital stay, and mortality between patients

118 infectious and noninfectious complications, length of hospital stay, and mortality in patients under

119 ere infections, noninfectious complications, length of hospital stay, and mortality.

120 r in demographics, clinical characteristics, length of hospital stay, and mortality.

121 outcomes evaluated were inpatient mortality, length of hospital stay, and nonoperative management.

122 APT-related findings, injury severity score, length of hospital stay, and number of mortalities.

123 ory drugs, Charlson Comorbidity Index score, length of hospital stay, and number of outpatient visits

124 of AKI accurately predicts 30-day mortality, length of hospital stay, and organ failure.

125 atient demographics, medications, diagnoses, length of hospital stay, and out-of-pocket drug costs as

126 e of complicated appendicitis, postoperative length of hospital stay, and overall duration of postope

127 as been associated with increased morbidity, length of hospital stay, and overall health care costs.

128 es determined bedside radiography use, total length of hospital stay, and patient outcome (mortality

129 reduced transfusion requirements, shortened length of hospital stay, and promising long-term outcome

130 orbidity and mortality, rate of reoperation, length of hospital stay, and rate of stoma closure at 6

131 e mortality, rate of surgical complications, length of hospital stay, and rates of hospital readmissi

132 luded postoperative morbidity and mortality, length of hospital stay, and readmission rate.

133 ction, intra-abdominal abscess, reoperation, length of hospital stay, and readmission.

134 ction, intra-abdominal abscess, reoperation, length of hospital stay, and readmission.

135 The primary endpoint was length of hospital stay, and secondary endpoints were te

136 mptoms, duration of intravenous antibiotics, length of hospital stay, and sequelae of disease (ptosis

137 ss transfusion requirement, slightly reduced length of hospital stay, and slightly reduced complicati

138 therapy but at a cost of early deaths, long length of hospital stay, and substantial transfusional s

139 s, the necessity of operative revisions, the length of hospital stay, and the length of intensive car

140 es, complication rates, pathologic findings, length of hospital stay, and total hospital costs were c

141 day mortality, hospital-acquired infections, length of hospital stay, and ventilator-free days, using

142 we could not measure statistically increased length of hospital stay associated with SSI, a represent

143 The recorded outcomes were length of hospital stay, bacterial infection, rebleeding

144 involvement of full-time ICU physicians and length of hospital stay before ICU admission.

145 s no statistically significant difference in length of hospital stay between children receiving beta-

146 umber of complications, hospital admissions, length of hospital stay, biochemical and anthropometric

147 h regard to frequency of reoperations or the length of hospital stay, but use of HES 130/0.4 was both

148 r Surgery protocols have resulted in shorter length of hospital stay by 30% to 50% and similar reduct

149 On univariate analysis, the length of hospital stay correlated with LV mass index.

150 In multivariate analysis, length of hospital stay correlated with the increased we

151 Total length of hospital stay (days) within 12 months was shor

152 Secondary outcome measures were mortality, length of hospital stay, days in intensive care unit, an

153 ies increased, and in-hospital mortality and length of hospital stay declined.

154 The median length of hospital stay decreased from 12 days (IQR 7-18

155 he years after implementation of the policy, length of hospital stay decreased more than expected fro

156 In patients without ACS, the median length of hospital stays decreased by 2.9 hours (95% con

157 Both mortality and length of hospital stay diminished significantly in peri

158 ysis, recipient age, serum creatinine, donor length of hospital stay, donor female gender, United Net

159 ated with risk were sex, treatment response, length of hospital stay, drug potency, daily dose (in mg

160 f reoperations, hospital readmissions, total length of hospital stay during 12 months, and adverse ev

161 r perioperative complications, and decreased length of hospital stay, especially when compared to an

162 cipient age, urgent status, donor age, donor length of hospital stay, etiology of liver disease, retr

163 Length of hospital stay, excluding any preoperative days

164 emonstrated less postoperative pain, shorter length of hospital stay, fewer wound-related complicatio

165 izations for device-related indications, the length of hospital stay for any cause was significantly

166 l of education, and parity, the mean (+/-SE) length of hospital stay for delivery was significantly (

167 The primary outcome was the mean length of hospital stay for delivery.

168 The mean length of hospital stay for intra-abdominal patients who

169 ssociated with increases in cost of care and length of hospital stay for patients with chest pain and

170 Average length of hospital stay for the >/= 70-year age group wa

171 Median length of hospital stay for the entire series was 4 days

172 gth of stay, 5 reported significantly longer lengths of hospital stay for obese children.

173 tigated the survival discharge rates and the length of hospital stay from cardiac arrest to discharge

174 OR, 1.40 [95% CI, 1.38-1.42]) and prolonged length of hospital stay (>6 days) among both women with

175 re now <5% at major centers, and the average length of hospital stay has been reduced to <2 weeks.

176 complications requiring hospitalization and length of hospital stay has not been quantified epidemio

177 um was an independent predictor of increased length of hospital stay (hazard ratio 1.63; 95% CI 1.11-

178 y-acquired severe sepsis, with higher median length of hospital stay (hospital acquired [17 d] vs hea

179 ed 6 months after discharge from the ICU for length of hospital stay, hospital mortality, and 6-month

180 Pregnancy outcomes included length of hospital stay, hypertensive disorders includin

181 cognized, is ineffective in reducing overall length of hospital stay, ICU days, nonbeneficial treatme

182 icant differences in the length of ICU stay, length of hospital stay, ICU mortality, and in-hospital

183 nd monitored for numerous factors, including length of hospital stay, immunosuppressive regimen, and

184 ucing unnecessary antibiotic use, shortening length of hospital stay, improving influenza detection a

185 as also associated with a decrease in median length of hospital stay in all patients (unadjusted p<.0

186 yield, reduced hospital admission and total length of hospital stay in intermediate-risk patients.

187 Mortality and length of hospital stay in patients treated with an acti

188 rdiac, respiratory, renal complications, and length of hospital stay in patients undergoing elective

189 effect on the incidence of infection or the length of hospital stay in these patients.

190 Length of hospital stay, in-hospital mortality, and cumu

191 Outcomes assessed included the length of hospital stay, in-hospital mortality, and over

192 ter mortality (OR: 2.30, 95% CI: 1.01-5.24), lengths of hospital stay (incidence rate ratio: 3.34, 95

193 unction, length of intensive care unit stay, length of hospital stay, inotropic support, and survival

194 Reduction in length of hospital stay is a veritable target in reducin

195 We also evaluated later outcomes: length of hospital stay, later medical visits or admissi

196 stroke were predetermined primary outcomes; length of hospital stay, length of intensive care unit s

197 ed if they were younger than 18 years, had a length of hospital stay less than 2 days, or had preexis

198 ds ratios for associations between age, sex, length of hospital stay, level of education, income, com

199 nd plasma NGAL levels associated with longer length of hospital stay, longer intensive care unit stay

200 etric measures and clinical variables [e.g., length of hospital stay (LOS) and infection rates].

201 , and how well nutritional variables predict length of hospital stay (LOS) in patients receiving ERAS

202 al Screening Tool (MUST) and its relation to length of hospital stay (LOS) in the general hospital po

203 Outcome measures were a length of hospital stay (LOS) of >/=3 days and intensive

204 The length of hospital stay (LOS) varied across reports (1.9

205 (ii) morbidity, (iii) transfusion rate, (iv) length of hospital stay (LOS), and (v) long-term surviva

206 oints included nausea score, days to flatus, length of hospital stay (LOS), and postoperative morbidi

207 dual liver volume per standard liver volume, length of hospital stay (LOS), complications, and readmi

208 Rates of death and complications, length of hospital stay (LOS), hospital cost, acute read

209 tcomes included infection-related mortality, length of hospital stay (LOS), infection-related LOS, in

210 CTO20, respectively), need for pleurodesis, length of hospital stay (LOS), operation during winter r

211 omplicated UTI, as defined by these QIs, and length of hospital stay (LOS).

212 independent effect of NIs on the outcomes of length of hospital stay (<7 d and >/=7 d) and readmissio

213 st for heterogeneity, p =.049) and a reduced length of hospital stay (mean reduction of 2.2 days; 95%

214 en endoscopic therapy and medical therapy in length of hospital stay (mean, 6.8 vs 5.6 days; P = .27)

215 dence interval [CI]): 0.64 (0.55, 0.74)] and length of hospital stay [mean difference (95% CI): -1.88

216 groups for early and late complications and lengths of hospital stay measured in postoperative hours

217 as a first step had a significantly shorter length of hospital stay (median, 5 days [interquartile r

218 95% CI, 4.67-8.00; p < 0.01), to have longer lengths of hospital stay (median, 31 d vs 13 d; p < 0.01

219 h small numbers, have shown no difference in length of hospital stay, morbidity, and mortality betwee

220 Length of hospital stay, mortality rate, and long-term n

221 To compare length of hospital stay, mortality, and readmission in a

222 Outcome measures such as length of hospital stay, mortality, incidence of infecti

223 tcome measures were days in the ICU; overall length of hospital stay; mortality; nonbeneficial treatm

224 h markers of acute illness burden, including length of hospital stay (odds ratio [OR], 1.02 [95% CI,

225 ' age >60 years (OR = 1.2, 95% CI; 1.1-1.3), length of hospital stay of >7 days (OR = 1.1, 95% CI; 1.

226 Full ID patients had an average length of hospital stay of 12.1 days/patient; that of li

227 IV within seven days of admission had a mean length of hospital stay of 2.2 weeks, and early treatmen

228 toxicities were minimal, as seen by a median length of hospital stay of 7 days (between days 0-100).

229 ce of VRE also occurs with a decrease in the length of hospital stay of colonized patients, increased

230 cluded operative time, estimated blood loss, length of hospital stay, operative complications, percen

231 There was no significant difference in length of hospital stay or complication rate comparing t

232 pients, there was no difference in median of length of hospital stay or incidence of overall complica

233 no benefit of this assay with respect to the length of hospital stay or vancomycin use.

234 y (OR, 2.65; 95% CI, 1.24-5.67; P = .03) and length of hospital stay (OR, 1.06; 95% CI, 1.02-1.11; P

235 izations, and night shift, but not with sex, length of hospital stay, or hospital unit.

236 e need for invasive ventilatory support, the length of hospital stay, or the 30-day mortality in pati

237 ot significantly differ for quality of life, length of hospital stay, or the primary outcome in the p

238 riappendiceal inflammatory stranding and the length of hospital stay (P < .001).

239 Increased length of hospital stay (P < 0.001) and antibiotic treat

240 Patients with delirium had longer length of hospital stay (P < 0.001) and greater likeliho

241 ation of antibiotics therapy (P < 0.05), and length of hospital stay (P < 0.05) were significantly lo

242 y nasosorption (but not NPA) correlated with length of hospital stay (P = .04) and requirement for me

243 ; 0.22 to 0.89; p=0.0250), and 1-day shorter length of hospital stay (p=0.0091).

244 erative and warm ischemia times, blood loss, length of hospital stay, pain score, convalescence, qual

245 e to peak lactate, intensive care unit stay, length of hospital stay, peak glucose, inotropic dose, g

246 US hospitals also had substantially shorter lengths of hospital stay, perhaps reflecting more effici

247 or failure, complications, re-interventions, length of hospital stay, physical and mental health scor

248 The median length of hospital stay post transplant was also similar

249 Both interventions reduced length of hospital stay, postconditioning -4 days [95% C

250 tages over open appendectomy with respect to length of hospital stay, rate of routine discharge, and

251 tions, operative time, postoperative nausea, length of hospital stay, recurrence, morbidity, and mort

252 ents had higher odds of exceeding the median length of hospital stay relative to whites.

253 nfidence interval (CI): 0.81, 0.98) and mean length of hospital stay shorter (-7.23 days, 95% CI: -10

254 Data on length of hospital stay, sick leave, socioeconomic param

255 hyperkalemia, the prevalence of hypotension, length of hospital stay, stroke, and death.

256 a shorter duration of treatment and shorter length of hospital stay than treatment with oral morphin

257 uality and intense pressure to safely reduce length of hospital stays, that led to the remarkable gro

258 icts the severity of acute pancreatitis, the length of hospital stay, the need of intensive care and

259 Secondary clinical end points were the length of hospital stay, the percentage of infants who r

260 emia times, blood loss, donor complications, length of hospital stay, time to return to work, and del

261 spect to the need for surgical intervention, length of hospital stay, transfusion requirement, and mo

262 A: 39.8 +/- 2.6 minutes, P = 0.38), and mean length of hospital stay (TVA: 1.1 +/- 0.1 days vs. LA: 1

263 In 227 (44.8%) episodes, the length of hospital stay was >/=8 h (median 22 h, IQR 16-

264 The mean length of hospital stay was 1.0 +/- 0.3 day for the devi

265 Average length of hospital stay was 10 +/- 0.3 days, with 1.5 +/

266 Mean length of hospital stay was 21.5 +/- 14.0 days.

267 Median length of hospital stay was 23 days (range, 0-76) for th

268 Mean length of hospital stay was 4.2 days (range, 3-7 days).

269 The median length of hospital stay was 6 days for all strategies, a

270 Mean length of hospital stay was 6 days for those completed l

271 The mean length of hospital stay was 6.4+/-7.3 days with a mean+/

272 Perioperative morbidity was 25%, the median length of hospital stay was 8 (range, 4-24) days, and th

273 The median postoperative length of hospital stay was 9 days in both groups.

274 in D deficiency subgroup analysis (n = 200), length of hospital stay was not significantly different

275 The median (IQR) length of hospital stay was not significantly different

276 Length of hospital stay was reduced in the levosimendan

277 Length of hospital stay was shorter after training (9 [7

278 ver, the complication rate was lower and the length of hospital stay was shorter for device closure t

279 Median length of hospital stay was shorter for laparoscopic GBP

280 However, the length of hospital stay was shorter for patients who und

281 Median length of hospital stay was significantly longer in the

282 Mean length of hospital stay was significantly longer in tran

283 ter laparoscopic colectomy (P < 0.0001), but length of hospital stay was significantly lower (P < 0.0

284 .1%, n = 16 vs 29.3%, n = 56; P = .001), and length of hospital stay was significantly reduced (4.6 d

285 The median postoperative length of hospital stay was significantly shorter in the

286 Length of hospital stay was the primary outcome.

287 Although length of hospital stay was the same in both groups, ris

288 Individual components of NACEs and length of hospital stay were secondary endpoints.

289 Venous ammonia at day 5 and length of hospital stay were significantly lower in the

290 Duration of RRT and length of hospital stay were significantly shorter in th

291 e, incidence and grade of complications, and length of hospital stay were similar between the 2 group

292 an number of days until drainage removal and length of hospital stay were similar in both groups (7 a

293 omplications, while the mortality and median length of hospital stay were similar to those of patient

294 Hospitalization rates and lengths of hospital stay were compared between the 2 gro

295 ata, stratified according to patient age and length of hospital stay, were used to estimate the total

296 ive and arousal domains were associated with length of hospital stay, while the negative valence and

297 ipasemia, pain levels, use of analgetics and length of hospital stay will be evaluated.

298 Primary outcome measure was length of hospital stay, with between-group differences

299 ent and reduced hospital admission and total length of hospital stay without affecting recurrent sync

300 ention on dyspnea relief (using 2 measures), length of hospital stay, worsening heart failure to 5 da